CYP1A1 and chronic myelogenous leukemia, BCR-ABL1 positive: In contrast, the prevalence of the mutant allele CYP1A1*2C in an Egyptian study was 3.3% in Ph+ve CML patients and 45% in controls (OR = 0.042, 95% CI: 0.005–0.373; p = 0.001) [38].